Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to screening procedures~2. Eastern Cooperative Oncology Grou (ECOG) Performance Status of 0, 1, or 2.~3. Patient with diagnosis of Ph+ CML-CP associated with BCR-ABL quantifiable by RQ-PCR (IS).~4. Patient has received a minimum of 3 months of imatinib or dasatinib treatment (any dose) since initial diagnosis with a documented response.~5. Patient is eligible for Pharmaceutical Benefits Scheme (PBS) reimbursed 1st line TKI treatment.~6. Patient has experienced non-hematological Adverse Events (AE(s)) of any grade, which persisted for at least 1 month despite supportive care or recurred at any grade at least once. Patients who, at the Investigator's discretion, require immediate discontinuation due to the severity of the adverse event are also eligible.~7. No other current or planned anti-leukemia therapies.~8. Adequate organ function.~9. Potassium, Magnesium and Total Calcium above Lower limit of normal.~10. life expectancy of more than 12 months in the absence of any intervention~Key Exclusion Criteria:~1. Prior treatment with nilotinib.~2. Prior Accelerated Phase (AP), Blast Crisis (BC) or allogeneic-transplant (unless the patient received an autologous transplant and was in Chrionic Phase (CP) prior to transplant and never in AP or BC).~3. Patient has documented Molecular Response (MR) 4.5 at the time of study entry~4. Patients with atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.~5. Known impaired cardiac function.~6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.~7. Pregnant or breast feeding (lactating) women.~8. Women of child-bearing potential unwilling or unable to use highly effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.

Based on this trial design, predict the completion outcome and termination type (if applicable).